![]() | Up a level |
Journal Article
Baertsch, Marc-Andrea, Schlenzka, Jana, Lisenko, Katharina, Krzykalla, Julia, Becker, Natalia, Weisel, Katja, Noppeney, Richard, Martin, Hans, Lindemann, Hans W., Haenel, Mathias, Nogai, Axel, Scheid, Christof, Salwender, Hans ORCID: 0000-0001-7803-0814, Fenk, Roland, Graeven, Ullrich, Reimer, Peter, Schmidt-Hieber, Martin, Goerner, Martin, Schmidt-Wolf, Ingo G. H., Klein, Stefan, Ho, Anthony D., Goldschmidt, Hartmut and Wuchter, Patrick
(2017).
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Eur. J. Haematol., 99 (1).
S. 42 - 51.
HOBOKEN:
WILEY.
ISSN 1600-0609
Baertsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., Merz, Maximilian, Hillengass, Jens, Raab, Marc S., Hose, Dirk, Wuchter, Patrick, Ho, Anthony D. ORCID: 0000-0002-1656-0833, Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo G. H., Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans
ORCID: 0000-0001-7803-0814, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans W., Martin, Hans, Noppeney, Richard, Weisel, Katja and Goldschmidt, Hartmut
(2016).
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer, 16.
LONDON:
BMC.
ISSN 1471-2407
Merz, Maximilian, Jauch, Anna, Hielscher, Thomas, Bochtler, Tilmann, Schoenland, Stefan Olaf, Seckinger, Anja, Hose, Dirk, Bertsch, Uta, Neben, Kai, Raab, Marc Steffen, Hillengass, Jens, Salwender, Hans, Blau, Igor Wolfgang, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo G. H., Scheid, Christof, Haenel, Mathias, Weisel, Katja C. and Goldschmidt, Hartmut (2018). Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv., 2 (1). S. 1 - 10. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 2473-9537
Merz, Maximilian, Salwender, Hans, Haenel, Mathias, Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Mai, Elias Karl ORCID: 0000-0002-6226-1252, Hose, Dirk, Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo G. H., Gerecke, Christian, Lindemann, Hans Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan and Goldschmidt, Hartmut
(2014).
Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma - Subgroup Analysis from the GMMG-MM5 Trial.
Blood, 124 (21).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
Vogt, Annabelle, Sievers, Elisabeth, Lukacs-Kornek, Veronika, Decker, Georges, Raskopf, Esther, Meumann, Nadja, Buening, Hildegard, Sauerbruch, Tilman, Strassburg, Christian P., Schmidt-Wolf, Ingo G. H. and Gonzalez-Carmona, Maria A. (2014). Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int., 34 (3). S. 447 - 462. HOBOKEN: WILEY-BLACKWELL. ISSN 1478-3231